A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer

clinical trial

A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer is …
instance of (P31):
clinical trialQ30612

External links are
P3098ClinicalTrials.gov IDNCT00090545

P6099clinical trial phasephase II clinical trialQ42824440
P17countryUnited States of AmericaQ30
P582end time2007-09-01
P921main subjectmetastatic prostate carcinomaQ55779807
P2899minimum age18
P1132number of participants46
P6153research siteNational Cancer InstituteQ664846
P580start time2004-09-01
P8363study typeinterventional studyQ78089383
P1476titleA Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer

Search more.